Evidence map›Paper›PMID 37889874›Full record

ArticleNano letters2023

Nanoreporter Identifies Lysosomal Storage Disease Lipid Accumulation Intracranially.

Merav Antman-Passig, Zvi Yaari, Dana Goerzen, Rooshi Parikh, Savannah Chatman, Lauren E Komer, Chen Chen, Emma Grabarnik, Mickael Mathieu, Adriana Haimovitz-Friedman and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nano letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Merav Antman-PassigMemorial Sloan Kettering Cancer Center, New York, New York 10065, United States.ORCID 0000-0003-2102-9139
Zvi YaariMemorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Dana GoerzenMemorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Rooshi ParikhThe City College of New York, New York, New York 10031, United States.
Savannah ChatmanDepartment of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri 63130, United States.
Lauren E KomerHelen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York 10065, United States.
Chen ChenMemorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Emma GrabarnikMemorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Mickael MathieuDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York10065, United States.
Adriana Haimovitz-FriedmanDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York10065, United States.
Daniel A HellerMemorial Sloan Kettering Cancer Center, New York, New York 10065, United States.ORCID 0000-0002-6866-0000
Memorial Sloan Kettering Cancer Center · USCity College of New York · USCornell University · USScripps College · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Tumor-Selective Delivery Approaches for MedulloblastomaR01NS116353 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, RAJU, PRAVEEN B. · 2020 to 2024
$3.1M
Inducing Neural Maturation in Medulloblastoma by Targeting EZH2R01NS122987 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAJU, PRAVEEN B., SNUDERL, MATIJA · 2022 to 2025
$2.8M
NCI NIH HHS P30 CA008748NCI NIH HHS U54 CA132378NINDS NIH HHS R01 NS116353NINDS NIH HHS R01 NS122987
6 · The paper itself

Abstract

Dysregulated lipid metabolism contributes to neurodegenerative pathologies and neurological decline in lysosomal storage disorders as well as more common neurodegenerative diseases. Niemann-Pick type A (NPA) is a fatal neurodegenerative lysosomal storage disease characterized by abnormal sphingomyelin accumulation in the endolysosomal lumen. The ability to monitor abnormalities in lipid homeostasis intracranially could improve basic investigations and the development of effective treatment strategies. We investigated the carbon nanotube-based detection of intracranial lipid content. We found that the near-infrared emission of a carbon nanotube-based lipid sensor responds to lipid accumulation in neuronal and in vivo models of NPA. The nanosensor detected lipid accumulation intracranially in an acid sphingomyelinase knockout mouse via noninvasive near-infrared spectroscopy. This work indicates a tool to improve drug development processes in NPA, other lysosomal storage diseases, and neurodegenerative diseases.

Indexed as

Lysosomal Storage DiseasesNanotubes, CarbonNeurodegenerative DiseasesAnimalsLysosomesMiceNeuronsSphingomyelinsNanotubes, CarbonSphingomyelinsbiosensorcarbon nanomaterialsneurodegenerative diseaseNiemann−Picksphingomyelin

Identifiers

PMID37889874
PMCPMC11246544
OpenAlexW4387970596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.